ATU-3 Risk of severe COVID-19 outcomes associated with inflammatory bowel disease medications: Reassuring insights from PREPARE-IBD

Autor:	Christopher Lamb, Shaji Sebastian, Alexandra J Kent, Jonathan P Segal, Haidee A Gonzalez, Matthew J Brookes, Shameer J Mehta, Sreedhar Subramanian, Neeraj Bhala, Lucy C Hicks, Thomas E Conley, Kamal V Patel, Gareth J Walker, Nicholas A Kennedy
Rok vydání:	2021
Předmět:	2019-20 coronavirus outbreak medicine.medical_specialty Coronavirus disease 2019 (COVID-19) business.industry Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Biologic therapies medicine.disease Inflammatory bowel disease chemistry.chemical_compound Mesalazine chemistry Internal medicine Pandemic medicine business
Zdroj:	Abstracts of distinction.
DOI:	10.1136/gutjnl-2021-bsg.41
Popis:	ATU-3 Frigure 1ConclusionsOur data provide reassurance for the continued evidence-based use of corticosteroids, immunomodulators and biologic therapies in IBD during the ongoing COVID-19 pandemic, and is consistent with an as yet unexplained association between mesalazine use and severe COVID-19 outcomes.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3ba0ee382ccd7cd99722dd64c7b96fc3 https://doi.org/10.1136/gutjnl-2021-bsg.41 Zobrazit plný text záznamu